Find your next paid study

Dana-Farber Cancer InstituteNCT06366347

~$10 – $7,500

Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma

A Phase 2 Non-comparative Screening Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy

This is a phase II, two-arm, noncomparative screening study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, admin…

Tufts Medical CenterNCT07718854

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase t…

M.D. Anderson Cancer CenterNCT01746836

Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements

This study investigates the role of intraoperative shear wave elastography ultrasound (ISWEU) in identifying healthy brain and tumor tissue stiffness differenc…

Brain TumorRecurrent Brain TumorBrain Neoplasm+1 more

~$10 – $750

Mayo ClinicNCT06630338

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

~$10 – $7,500

Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivoluma…

H. Lee Moffitt Cancer Center and Research InstituteNCT05681780

Head and Neck CancerRelapseRecurrent+1 more

Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)

The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells agains…

UNC Lineberger Comprehensive Cancer CenterNCT06096038

Recurrent Multiple MyelomaRefractory Multiple Myeloma

Pharmacodynamically Monitored Linvoseltamab Dosing De-Escalation in Relapsed Multiple Myeloma

This phase I/II trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myelo…

Fred Hutchinson Cancer CenterNCT07181941

Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaStage IV Nasopharyngeal Carcinoma AJCC v8

A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come ba…

National Cancer Institute (NCI)NCT06029270

~$10 – $5,625

Glioma, Recurrent High GradeGrade 4 Malignant Glioma

A Phase 0/1 Study of NST-628 in Participants With Recurrent Grade 4 Glioma Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD) Triggered Expansion Cohort

This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high pho…

Recurrent CNS TumorsBrain CancerGliomas+3 more

~$10 – $7,500

Nader SanaiNCT07784985

Observational

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fa…

National Cancer Institute (NCI)NCT07374692

~$10 – $5,625

Residual, Progressive or Recurrent Grade II or III Meningioma

An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (per…